Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

Fig. 6

Correlation between the presence of TAI cells in the TME and tumor growth. (a) Regimen scheme of (combinatorial) antibody treatment after tumor injection. (b) Comparison of tumor growth between control group (n = 9), PD-L1 antibody treated group (n = 9), PD-L1 and ICOS antibody treated group (n = 11), PD-L1 and LAG-3 antibody treated group (n = 10). (c) Survival curves for each treatment mentioned above. (d) Study of the tumor-microenvironment after control (n = 6), single therapy (PD-L1, n = 8) or combinatorial therapy (PD-L1 and ICOS, n = 6) of the CD8+ TAI-like cells (left panel) and CD4+ TAI-like cells (right panel) at day 8 (unpaired t-test) displayed on a per-mouse basis with mean ± SEM

Back to article page